Here is the dividend forecast to 2028 for CSL shares

Are investors going to get healthy dividends from this stock?

| More on:
A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have done very well for investors over the long term. The CSL share price has lifted around 300% over the past decade. Is the CSL dividend forecast looking optimistic for the ASX healthcare share? I'm going to look at that in this article.

The company is known for many elements, including its vaccines, blood plasma collection and related products, and more. It's a very large biotechnology business with a market capitalisation of $134.6 billion.

CLS has achieved significant profit growth over the past decade, which has helped fund impressive dividend growth over that period. We're going to look at how far the broker UBS thinks the CSL dividend could rise.

FY24 projection

CSL had a solid start to the 2024 financial year. In the first half of FY24, revenue increased 11% to $8.05 billion and net profit after tax (NPAT) rose 17% to $1.9 billion, while underlying net profit (NPATA) rose by 11%.

For FY24, CSL expects underlying profit to be between $2.9 billion and $3 billion, representing growth of 13% to 17%.

UBS thinks the ASX healthcare share can achieve a dividend per share of US$2.60 in FY24, which would represent an increase of around 10%. In Australian dollar terms, that would be an annual dividend payout of $3.98 for CSL shares, which would represent a dividend yield of 1.5%.

How about FY25?

The ASX healthcare share is expected to see a good increase in profitability over the next few years.

UBS suggests the net profit could grow by 18.5% to $3.6 billion. The broker thinks the dividend might be hiked by another 10% to US$2.86 per share.

And FY26?

Next, the 2026 financial year could see more profit growth for the ASX healthcare share, which could rise 19.6% to US$4.3 billion.

If that impressive profit growth occurs, it could enable a 9.8% increase in the CSL dividend to US$3.14 per share.

Expectations for FY27

The 2027 financial year may see another good result for CSL, with a possible profit rise of 20%. If that happens, the dividend growth could be 10.2% to US$3.46 per share.

Finally, here's the FY28 forecast

It's a long way away, but the current suggestion by UBS is that CSL's profit could grow 10.9% to $5.7 billion in FY28. If CSL achieves that, it would mean the net profit could rise by almost 90% between FY24 to FY28.

CSL's dividend per share in FY28 could reach US$3.80 per share, which would be A$5.82. At the current CSL share price, that would be a dividend yield of 2.1%, which isn't exactly a huge yield, but would represent a good growth rate compared to FY24.  

While it's impossible to know what's going to happen, CSL is giving itself a good chance of growth thanks to the billions of dollars it's investing in research and development to create new products and build new earnings streams.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »